Quince Therapeutics (NASDAQ:QNCX) vs. Omega Therapeutics (NASDAQ:OMGA) Head-To-Head Comparison

Quince Therapeutics (NASDAQ:QNCX) and Omega Therapeutics (NASDAQ:OMGA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and target prices for Quince Therapeutics and Omega Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	0	0	0	0	N/A
Omega Therapeutics	0	0	4	0	3.00

Omega Therapeutics has a consensus target price of $11.00, indicating a potential upside of 248.10%. Given Omega Therapeutics’ higher probable upside, analysts clearly believe Omega Therapeutics is more favorable than Quince Therapeutics.

Volatility and Risk

Quince Therapeutics has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Omega Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.

Earnings and Valuation

This table compares Quince Therapeutics and Omega Therapeutics’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$51.66 million	N/A	N/A
Omega Therapeutics	$2.07 million	84.18	-$102.70 million	($2.22)	-1.42

Quince Therapeutics has higher earnings, but lower revenue than Omega Therapeutics.

Insider and Institutional Ownership

39.6% of Quince Therapeutics shares are held by institutional investors. Comparatively, 92.7% of Omega Therapeutics shares are held by institutional investors. 21.0% of Quince Therapeutics shares are held by company insiders. Comparatively, 57.0% of Omega Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Quince Therapeutics and Omega Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-32.02%	-30.92%
Omega Therapeutics	-4,283.72%	-97.34%	-63.64%

About Quince Therapeutics

Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

About Omega Therapeutics

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.